GLYZIAMET 50/500MG TABLET

GLYZIAMET 50/500MG TABLET contains a combination of two active ingredients: Sitagliptin & Metformin. Sitagliptin belongs to the class of medications known as dipeptidyl peptidase-4 (DPP-4) inhibitors, while Metformin is a biguanide antidiabetic medication. This combination medication is used to manage type 2 diabetes by controlling blood sugar levels through different mechanisms of action.

Sitagliptin:

Sitagliptin works by increasing the levels of incretin hormones in the body, which stimulate the release of insulin from the pancreas and inhibit the release of glucagon, thereby reducing blood sugar levels after meals.

Metformin:

Metformin primarily works by reducing glucose production in the liver and improving insulin sensitivity in muscle tissue, thereby lowering both fasting and postprandial blood glucose levels.

Uses:

GLYZIAMET 50/500MG TABLET is prescribed for the management of type 2 diabetes mellitus in adults. It helps improve glycemic control by lowering blood sugar levels, thus reducing the risk of complications associated with diabetes, such as cardiovascular disease, kidney damage, and nerve damage.

Administration:

GLYZIAMET 50/500MG TABLET is typically taken orally with meals, usually once or twice daily, as directed by a healthcare professional. The dosage may vary depending on individual patient factors, including kidney function and response to treatment. It is important to adhere to the prescribed dosage regimen and maintain regular monitoring of blood glucose levels.

Side Effects:

Common side effects of GLYZIAMET 50/500MG TABLET may include:

• Nausea or vomiting
• Diarrhea
• Abdominal discomfort or bloating
• Headache
• Hypoglycemia (low blood sugar) when used with other antidiabetic medications
• Upper respiratory tract infection
• Hypersensitivity reactions (rash, itching)

Precautions:

Before using GLYZIAMET 50/500MG TABLET, patients should inform their healthcare provider about any pre-existing medical conditions, allergies, or medications they are currently taking. It is important to monitor kidney function regularly, as Metformin can affect renal function. GLYZIAMET should be used with caution in patients with a history of pancreatitis or those at risk of heart failure.

Contraindications:

GLYZIAMET 50/500MG TABLET is contraindicated in patients with a known hypersensitivity to Sitagliptin, Metformin, or any other components of the tablet. It should not be used in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²) or metabolic acidosis. GLYZIAMET should be discontinued temporarily before any procedure involving intravenous contrast media and restarted only after renal function is confirmed to be normal.

Conclusion:

GLYZIAMET 50/500MG TABLET, containing Sitagliptin and Metformin, is a combination medication used for the management of type 2 diabetes mellitus. It helps improve glycemic control by lowering blood sugar levels through different mechanisms of action. Patients should use this medication as directed by their healthcare provider and be aware of potential side effects.